[VP-16, vincristine, adriamycin and cyclophosphamide (EVAC) in patients with small-cell lung cancer].
Abad-Esteve
A
A
Rosell
R
R
Moreno
I
I
Fernández-Marcial
C
C
Roselló
M
M
Ribas Mundó
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin
VP-16, vincristina, adriamicina y ciclofosfamida (EVAC) en pacientes con cáncer de pulmón de células pequeñas.